240 related articles for article (PubMed ID: 19509145)
1. Toward an effective targeted chemotherapy for multiple myeloma.
Polson AG; Sliwkowski MX
Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
6. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
8. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT
Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123
[TBL] [Abstract][Full Text] [Related]
9. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
[TBL] [Abstract][Full Text] [Related]
11. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Schönfeld K; Zuber C; Pinkas J; Häder T; Bernöster K; Uherek C
J Hematol Oncol; 2017 Jan; 10(1):13. PubMed ID: 28077160
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of anti-myeloma cell antibody on human plasmacytoma model].
Kosaka M; Ozaki S
Rinsho Ketsueki; 1997 Apr; 38(4):275-80. PubMed ID: 9146050
[No Abstract] [Full Text] [Related]
13. Drug-conjugated monoclonal antibodies for the treatment of cancer.
Lambert JM
Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates as targeted cancer therapeutics.
Sun Y; Yu F; Sun BW
Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
[TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
16. [Targeting of antitumor drugs with monoclonal antibodies].
Monneret C; Florent JC
Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
[TBL] [Abstract][Full Text] [Related]
17. Antibody-targeted drugs for the therapy of cancer.
Pietersz GA; Krauer K
J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
[TBL] [Abstract][Full Text] [Related]
18. Antibody-maytansinoid conjugates for the treatment of myeloma.
Lutz RJ; Whiteman KR
MAbs; 2009; 1(6):548-51. PubMed ID: 20068397
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies with immunoconjugates.
Pietersz GA; Smyth MJ; Kanellos J; Cunningham Z; McKenzie IF
Targeted Diagn Ther; 1989; 2():73-97. PubMed ID: 2519551
[No Abstract] [Full Text] [Related]
20. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]